Rita Mazza

Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial

Daniela Cardinale, Fabio Ciceri, Roberto Latini et al. · European Journal of Cancer · 2018 · 224 citations

International Cardiooncology Society-one, Preventive Medicine, Cardiovascular Disease +9

Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study

Armando Santoro, Rita Mazza, Alessandro Pulsoni et al. · Journal of Clinical Oncology · 2016 · 95 citations · Full text

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo‐Stella, Rita Mazza, Salomon Manier et al. · Blood · 2022 · 86 citations

Predictive value of early 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high‐dose chemotherapy

Luca Castagna, Stéfania Bramanti, Monica Balzarotti et al. · British Journal of Haematology · 2009 · 48 citations · Full text

Oncologic Imaging, Pet-mri, Pathology +17

Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma

Armando Santoro, Rita Mazza, Alessandro Pulsoni et al. · Blood Advances · 2020 · 40 citations · Full text